{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:36:39Z","timestamp":1793644599291,"version":"4.5.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.intimp.2026.116712","type":"journal-article","created":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T09:01:55Z","timestamp":1777194115000},"page":"116712","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Inflachromene attenuates monocrotaline-induced pulmonary arterial hypertension by suppressing the HMGB1\u2013TLR4\/RAGE\u2013NF-\u03baB signaling pathway"],"prefix":"10.1016","volume":"180","author":[{"given":"Yueru","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Nuerlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilali","family":"Paizula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimuran","family":"Kawulijiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhayier","family":"Tueraili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.116712_bb0005","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/jama.2022.4402","article-title":"Diagnosis and treatment of pulmonary arterial hypertension","volume":"327","author":"Ruopp","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.intimp.2026.116712_bb0010","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.intimp.2026.116712_bb0015","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S2213-2600(24)00295-9","article-title":"Global, regional, and national burden of pulmonary arterial hypertension, 1990\u20132021: a systematic analysis for the global burden of disease study 2021","volume":"13","author":"Leary","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.intimp.2026.116712_bb0020","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41569-024-01064-4","article-title":"Mechanisms and treatment of pulmonary arterial hypertension","volume":"22","author":"Ghofrani","year":"2025","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.intimp.2026.116712_bb0025","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01830-2024","article-title":"Drugs targeting novel pathways in pulmonary arterial hypertension","volume":"66","author":"Sitbon","year":"2025","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.intimp.2026.116712_bb0030","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.tips.2025.05.004","article-title":"Anti-remodeling therapies in pulmonary arterial hypertension","volume":"46","author":"Boucherat","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.intimp.2026.116712_bb0035","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70134","article-title":"Pulmonary hypertension: molecular mechanisms and clinical studies","volume":"6","author":"Adu-Amankwaah","year":"2025","journal-title":"MedComm"},{"key":"10.1016\/j.intimp.2026.116712_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/jpm13020366","article-title":"Pulmonary vascular remodeling in pulmonary hypertension","volume":"13","author":"Jia","year":"2023","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.intimp.2026.116712_bb0045","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-025-02287-8","article-title":"Signaling pathways and targeted therapy for pulmonary hypertension","volume":"10","author":"Adu-Amankwaah","year":"2025","journal-title":"Sig. Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2026.116712_bb0050","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1016\/S0140-6736(22)01601-4","article-title":"The evolving landscape of pulmonary arterial hypertension clinical trials","volume":"400","author":"Weatherald","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2026.116712_bb0055","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41577-023-00894-6","article-title":"The multifunctional protein HMGB1: 50 years of discovery","volume":"23","author":"Tang","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2026.116712_bb0060","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-020-00950-x","article-title":"HMGB1 in inflammation and cancer","volume":"13","author":"Wang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2026.116712_bb0065","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nri1594","article-title":"High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal","volume":"5","author":"Lotze","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2026.116712_bb0070","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s12276-022-00736-w","article-title":"The mechanism of HMGB1 secretion and release","volume":"54","author":"Chen","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.intimp.2026.116712_bb0075","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/jcmm.13048","article-title":"Emerging role of HMGB1 in lung diseases: friend or foe","volume":"21","author":"Ding","year":"2017","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.intimp.2026.116712_bb0080","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s43556-025-00305-3","article-title":"Damage-associated molecular patterns (DAMPs) in diseases: implications for therapy","volume":"6","author":"Lin","year":"2025","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.intimp.2026.116712_bb0085","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.2119\/molmed.2012.00283","article-title":"High mobility group box 1 contributes to the pathogenesis of experimental pulmonary hypertension via activation of toll-like receptor 4","volume":"18","author":"Bauer","year":"2012","journal-title":"Mol. Med."},{"key":"10.1016\/j.intimp.2026.116712_bb0090","first-page":"3950","article-title":"HMGB1 affects the development of pulmonary arterial hypertension via RAGE","volume":"21","author":"Li","year":"2017","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.intimp.2026.116712_bb0095","doi-asserted-by":"crossref","first-page":"C175","DOI":"10.1152\/ajpcell.00148.2018","article-title":"HMGB1 is mechanistically essential in the development of experimental pulmonary hypertension","volume":"316","author":"Dai","year":"2019","journal-title":"Am. J. Phys. Cell Physiol."},{"key":"10.1016\/j.intimp.2026.116712_bb0100","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.vph.2018.12.006","article-title":"HMGB1\/TLR4 promotes hypoxic pulmonary hypertension via suppressing BMPR2 signaling","volume":"117","author":"Wang","year":"2019","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116712_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2025.110836","article-title":"YAP-mediated glycolysis promotes pulmonary arterial smooth muscle cell proliferation in pulmonary arterial hypertension","volume":"301","author":"Shi","year":"2025","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2026.116712_bb0110","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2147\/DDDT.S444605","article-title":"Forsythoside B mitigates monocrotaline-induced pulmonary arterial hypertension via blocking the NF-\u03baB signaling pathway to attenuate vascular remodeling","volume":"18","author":"Liu","year":"2024","journal-title":"DDDT"},{"key":"10.1016\/j.intimp.2026.116712_bb0115","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.211201","article-title":"Inflachromene inhibits autophagy through modulation of Beclin 1 activity","volume":"131","author":"Kim","year":"2018","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.intimp.2026.116712_bb0120","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1038\/s41401-023-01087-6","article-title":"Inflachromene attenuates seizure severity in mouse epilepsy models via inhibiting HMGB1 translocation","volume":"44","author":"Dai","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.intimp.2026.116712_bb0125","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-023-02756-3","article-title":"HMGB1 mediates synaptic loss and cognitive impairment in an animal model of sepsis-associated encephalopathy","volume":"20","author":"Yin","year":"2023","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.intimp.2026.116712_bb0130","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/nchembio.1669","article-title":"A small molecule binding HMGB1 and HMGB2 inhibits microglia-mediated neuroinflammation","volume":"10","author":"Lee","year":"2014","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.intimp.2026.116712_bb0135","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1021\/acs.jmedchem.6b00954","article-title":"Treatment of sepsis pathogenesis with high mobility group box protein 1-regulating anti-inflammatory agents","volume":"60","author":"Cho","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.intimp.2026.116712_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110198","article-title":"Inflachromene inhibits intimal hyperplasia through the HMGB1\/2- regulated TLR4-NF-\u03baB pathway","volume":"119","author":"Teng","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2026.116712_bb0145","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jpba.2019.01.013","article-title":"A validated UPLC-MS\/MS method for pharmacokinetic study of inflachromene, a novel microglia inhibitor","volume":"166","author":"Lee","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.intimp.2026.116712_bb0150","doi-asserted-by":"crossref","first-page":"D1670","DOI":"10.1093\/nar\/gkae973","article-title":"Generic diagramming platform (GDP): a comprehensive database of high-quality biomedical graphics","volume":"53","author":"Jiang","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.intimp.2026.116712_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119347","article-title":"Galectin-3 participates in PASMC migration and proliferation by interacting with TGF-\u03b21","volume":"274","author":"Cao","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.intimp.2026.116712_bb0160","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1039\/D3SC06997D","article-title":"Inflachromene ameliorates parkinsons disease by targeting Nrf2-binding keap1","volume":"15","author":"Yim","year":"2024","journal-title":"Chem. Sci."},{"key":"10.1016\/j.intimp.2026.116712_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102482","article-title":"HMGB1 promotes the development of pulmonary arterial hypertension in rats","volume":"9","author":"Sadamura-Takenaka","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2026.116712_bb0170","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12931-014-0148-4","article-title":"Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats","volume":"15","author":"Yang","year":"2014","journal-title":"Respir. Res."},{"key":"10.1016\/j.intimp.2026.116712_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23052410","article-title":"Signal transduction during metabolic and inflammatory reprogramming in pulmonary vascular remodeling","volume":"23","author":"Gomes","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.116712_bb0180","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s10495-025-02086-0","article-title":"New insights into pulmonary arterial hypertension: interaction between PANoptosis and perivascular inflammatory responses","volume":"30","author":"Su","year":"2025","journal-title":"Apoptosis"},{"key":"10.1016\/j.intimp.2026.116712_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111555","article-title":"High-mobility group box 1 serves as an inflammation driver of cardiovascular disease","volume":"139","author":"Wahid","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2026.116712_bb0190","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3389\/fimmu.2020.00484","article-title":"Targeting inflammation driven by HMGB1","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116712_bb0195","article-title":"HMGB1: from molecular functions to clinical applications in cancer and inflammatory diseases","volume":"n\/a","author":"Guo","year":"2025","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.intimp.2026.116712_bb0200","doi-asserted-by":"crossref","first-page":"767","DOI":"10.4049\/jimmunol.1900860","article-title":"Interplay between RAGE and TLR4 regulates HMGB1-induced inflammation by promoting cell surface expression of RAGE and TLR4","volume":"205","author":"Zhong","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2026.116712_bb0205","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1189\/jlb.0713412","article-title":"High-mobility group box-1 and its role in angiogenesis","volume":"95","author":"Yang","year":"2014","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.intimp.2026.116712_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262211143","article-title":"The role of toll-like receptors and viral infections in the pathogenesis and progression of pulmonary arterial hypertension-a narrative review","volume":"26","author":"Stycze\u0144","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.116712_bb0215","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1146\/annurev-med-041316-085215","article-title":"Targeting RAGE signaling in inflammatory disease","volume":"69","author":"Hudson","year":"2018","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.intimp.2026.116712_bb0220","article-title":"NF-\u03baB and pulmonary hypertension: advances in mechanistic research and therapeutic applications","volume":"60","author":"Si","year":"2025","journal-title":"Am. Heart J. Plus Cardiol. Res. Pract."},{"key":"10.1016\/j.intimp.2026.116712_bb0225","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2022-000137","article-title":"Pathophysiology and new advances in pulmonary hypertension","volume":"2","author":"Bousseau","year":"2023","journal-title":"Bmjmed"},{"key":"10.1016\/j.intimp.2026.116712_bb0230","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.3390\/cells9112338","article-title":"Perivascular inflammation in pulmonary arterial hypertension","volume":"9","author":"Hu","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2026.116712_bb0235","doi-asserted-by":"crossref","DOI":"10.1007\/s00018-025-05923-2","article-title":"Rab26 promotes hypoxia-induced hyperproliferation of PASMCs by modulating the AT1R-STAT3-YAP axis","volume":"82","author":"You","year":"2025","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.intimp.2026.116712_bb0240","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3390\/pharmaceutics17020224","article-title":"Fundamental and targeted approaches in pulmonary arterial hypertension treatment","volume":"17","author":"Park","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.intimp.2026.116712_bb0245","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12931-023-02454-x","article-title":"HMGB1-induced activation of ER stress contributes to pulmonary artery hypertension in vitro and in vivo","volume":"24","author":"Zhang","year":"2023","journal-title":"Respir. Res."},{"key":"10.1016\/j.intimp.2026.116712_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106238","article-title":"Immunity and inflammation in pulmonary arterial hypertension: from pathophysiology mechanisms to treatment perspective","volume":"180","author":"Wang","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2026.116712_bb0255","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01761-2019","article-title":"Cellular sources of interleukin-6 and associations with clinical phenotypes and outcomes in pulmonary arterial hypertension","volume":"55","author":"Simpson","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.intimp.2026.116712_bb0260","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.14336\/AD.2020.0111","article-title":"Pathological mechanisms and potential therapeutic targets of pulmonary arterial hypertension: a review","volume":"11","author":"Xiao","year":"2020","journal-title":"Aging Dis."},{"key":"10.1016\/j.intimp.2026.116712_bb0265","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1164\/rccm.201201-0164OC","article-title":"Modern age pathology of pulmonary arterial hypertension","volume":"186","author":"Stacher","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.intimp.2026.116712_bb0270","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1165\/rcmb.2021-0091TR","article-title":"Basement membrane extracellular matrix proteins in pulmonary vascular and right ventricular remodeling in pulmonary hypertension","volume":"65","author":"Ambade","year":"2021","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.intimp.2026.116712_bb0275","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02341-2020","article-title":"Targeting transforming growth factor-\u03b2 receptors in pulmonary hypertension","volume":"57","author":"Guignabert","year":"2021","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.intimp.2026.116712_bb0280","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/cvr\/cvx051","article-title":"RAGE-mediated extracellular matrix proteins accumulation exacerbates HySu-induced pulmonary hypertension","volume":"113","author":"Jia","year":"2017","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.intimp.2026.116712_bb0285","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1161\/HYPERTENSIONAHA.120.16118","article-title":"Necrosis-released HMGB1 (high mobility group box 1) in the progressive pulmonary arterial hypertension associated with male sex","volume":"76","author":"Zemskova","year":"2020","journal-title":"Hypertension"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926005588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926005588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:56:22Z","timestamp":1778820982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926005588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":57,"alternative-id":["S1567576926005588"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116712","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflachromene attenuates monocrotaline-induced pulmonary arterial hypertension by suppressing the HMGB1\u2013TLR4\/RAGE\u2013NF-\u03baB signaling pathway","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116712","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116712"}}